Latest Mach7 Technologies (Asx:M7t) News

Mach7 Technologies has inked a five-year subscription agreement with UnityPoint Health, marking the first commercial deployment of its new Flamingo Architecture and setting the stage for significant recurring revenue growth.

Mach7 Technologies reports a modest rise in recurring revenue alongside a comprehensive commercial transformation, positioning itself for growth in AI-driven medical imaging.

Mach7 Technologies reports a pivotal first quarter for FY26, marked by the initial go-live of a major U.S. Veterans Health Administration contract, leadership changes, and a strategic business reset.

Mach7 Technologies has initiated Phase 1 of the Veterans Health Administration’s National Teleradiology Program, deploying its core imaging software across 125 sites. This milestone sets the stage for a potential $11.7 million contract and broader expansion within the VHA network.

Mach7 Technologies reported a robust FY25 with 16% revenue growth and a strategic pivot towards customer-centric innovation, underpinned by leadership changes and a strong financial position.

Mach7 Technologies reported a 16% revenue increase and a near break-even adjusted EBITDA in FY25, setting the stage for a strategic overhaul expected next year.

Mach7 Technologies Limited reported a 16% revenue increase to AUD 33.8 million for FY25, alongside a 22% reduction in net loss, driven by a strategic shift to subscription-based sales and disciplined cost management.

Mach7 Technologies has updated its FY25 guidance, reporting positive cash flow and a solid financial position, while appointing Teri Thomas as its new CEO to steer the company’s next growth phase.

Mach7 Technologies closes FY25 with solid recurring revenue growth, positive cash flow, and a refreshed leadership team focused on innovation and customer value.

Mach7 Technologies maintains its FY25 revenue growth guidance with strong recurring revenue gains, despite a modest shortfall in contracted annual recurring revenue. The company also advances its share buyback program, signaling confidence in its financial position.

Mach7 Technologies has expanded its partnership with a major US radiology marketplace, signing a five-year licence amendment worth A$5 million that extends the contract by three years and adds significant value.

Mach7 Technologies reported a robust Q3 FY25 with a CARR of A$30.8 million and positive operating cash flow, while announcing a leadership change and reaffirming growth guidance.